安旭生物(688075.SH)：2025年度净利润7338.21万元，同比下降61.84%

Core Viewpoint - Anxu Bio (688075.SH) reported a decline in both revenue and net profit for the fiscal year 2025, indicating challenges in maintaining growth amidst a competitive landscape [1] Financial Performance - The company achieved operating revenue of 453.58 million yuan, a decrease of 16.11% compared to the same period last year [1] - The net profit attributable to the parent company was 73.38 million yuan, down 61.84% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 15.37 million yuan, reflecting a decline of 59.44% year-on-year [1] Strategic Initiatives - The company focused on steady development of its core business, integrating existing high-quality technological resources [1] - There was a continuous strategic investment in new technology platforms, aimed at enhancing long-term competitive advantages in the industry [1] - The company advanced its operational upgrade centered on lean management, significantly improving operational efficiency and cost control [1] International Expansion - The company increased its efforts in establishing overseas branches, achieving positive progress in expanding its international market presence [1] - Correspondingly, sales expenses increased, which is expected to open up space for sustained growth in the future [1]